title: Skin tissue engineering.
abstract: The coverage of extensive wounds with viable autologous keratinocytes remains the only option of treatment if autologous donor skin is not obtainable. There is evidence that proliferating keratinocytes, as suspended cells or as a single layer, are adequate for wound closure. Understanding keratinocyte-matrix interactions not only allows us to influence keratinocyte outgrowth, adhesion, and migration, but may also guide us to modify matrix molecules for enhancing keratinocyte take. Further approaches may include the generation of genetically manipulated keratinocytes, which allow the use of an off-the-shelf epidermal replacement. As surgeons, our goal is to help burn patients with the best quality of skin in the shortest time possible. As tissue engineers, we have not achieved the goal of a universal skin product. By continually reviewing the options and using them, we can at least use the proper material in the adequate situation. Because of the limited resources, the need for comparisons of clinical effectiveness and cost are ever more important. As anatomy and physiology of engineered skin substitutes improve, they will become more similar to native skin autografts. Improvement of skin substitutes will result from inclusion of additional cell types (eg, melanocytes) and from modifications of culture media and scaffolds. Skin-substitute materials may be able to stimulate regeneration rather than repair, and tissue-engineered skin may match the quality of split-skin autografts, our present gold standard.
authors: Department of Plastic and Hand Surgery, University of Freiburg Medical Center, Hugstetter Str. 55, D-79106 Freiburg i. Br., Germany. bannasch@ch11.ukl.uni-freiburg.de
authors: H
authors: H
authors: Bannasch
authors: M
authors: M
authors: Föhn
authors: T
authors: T
authors: Unterberg
authors: A D
authors: AD
authors: Bach
authors: B
authors: B
authors: Weyand
authors: G B
authors: GB
authors: Stark
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D005337:Fibrin / Q000627:therapeutic use; D006801:Humans; D015603:Keratinocytes / Q000502:physiology; D023421:Models, Animal; D012038:Regeneration / Q000502:physiology; D012867:Skin / Q000293:injuries; D012879:Skin Physiological Phenomena; D016038:Skin Transplantation / Q000379:methods*; D017768:Skin, Artificial; D023822:Tissue Engineering / Q000379:methods*; D014182:Transplantation, Autologous / Q000379:methods
chemical_list: D005337:Fibrin